Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Democrats prioritize pricing, generics and drug safety

Article Abstract:

The Democrats reclaiming majorities in both the House of Representatives and Senate as of November 2006 assure changing political dynamics that would significantly affect drug pricing, research funding and other matters related to biotechnology. The House Democratic leadership passed legislation mandating the federal government to negotiate drug prices under the year-old Part D system providing $1 billion over three years for federal biodefense research.

Author: Fox, Jeffrey L.
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
Government expenditures, Government domestic functions, Legislative Bodies, US House of Representatives, US Senate, Science and technology policy, Democratic Party (United States), United States. Congress. Senate, United States. Congress. House, Government finance

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


US biotechnology companies and foreign nationals: The changing dynamics of access to H-1B visas

Article Abstract:

The reduction in the access of the H-1b visa for the foreign nationals have left the US biotech employers with limited number of expertise foreign nationals. Details of the changes in the H-1B visa program and measures taken to train the US workers are discussed.

Author: Dahms, A. Stephen, Trow, Stephen C.
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
Use of services, International aspects, Outsourcing, Work visas

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Price controls: Preparing for the unthinkable

Article Abstract:

The biotechnology companies are worried about the prospect of the price controls in the US market. The pressure in the US for introducing prescription drug price controls and also the factors used by companies to set a price in the US market are discussed.

Author: Herrera, Stephan
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
Commodity & service prices, Interpretation and construction, Prices and rates, Company pricing policy, Prescription pricing, Pharmaceutical laws

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Laws, regulations and rules, Biotechnology industry, Biotechnology industries, Government regulation
Similar abstracts:
  • Abstracts: Nestle King Size Butterfinger Crisp Candy Bar. Nestle Toll House Swirled Morsels. Stouffer's Frozen Family Size Italiano Lasagna
  • Abstracts: Do privatized banks in middle- and low-income countries perform better than rival banks? An intra-industry analysis of bank privatization
  • Abstracts: Do privatized banks in middle- and low-income countries perform better than rival banks? An intra-industry analysis of bank privatization. part 2
  • Abstracts: Calvin Klein Euphoria Fragrance for Women. Sweet Pea Tanning Emulsion
  • Abstracts: F0 generation mice fully derived from gene-targeted embryonic stem cells allowing immediate phenotypic analyses
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.